ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Cell > NY-ESO-1 > CHEK-STP114

NY-ESO-1 specific TCR-HEK293 cell line

ACROBiosystems can provide the customized peptide-MHC I complex service to accelerate your relevant research. Click here to learn more

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    NY-ESO-1 specific TCR-HEK293 cell line
  • Application

    Binding assay by FACS and cell based ELISA.

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (5 μg/mL)
  • Culture Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    10% DMSO + 90% FBS
  • Quantity
    NY-ESO-1 specific TCR-HEK293 cell line
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 NY-ESO-1 FACS

FACS analysis NY-ESO-1 specific TCR on NY-ESO-1 specific TCR-HEK293 cell line.
FACS assay shows that PE-Labeled Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein can bind to NY-ESO-1 specific TCR-HEK293 cell line. NY-ESO-1 specific TCR-HEK293 cell line was red line, Negative control HEK293 cells was grey line (QC tested).

Please contact us if you are interested in related cell pool service.

  • Background
    NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. This cell can specifically recognize HLA-A2/NY-ESO-1.
  • Limited Use&License Disclosure
    1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : Inquire

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:16 Details
  • Latest Research Phase:Phase 2 Clinical

データシート&ドキュメンテーション

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone